FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2937138488> ?p ?o ?g. }

• W2937138488 endingPage "3284" @default.
• W2937138488 startingPage "3284" @default.
• W2937138488 abstract "Abstract Background: Engraftment syndrome (ES) has been observed post autologous hematopoietic stem cell transplantation (ASCT) in patients with multiple myeloma (MM), and may require treatment with immunosuppressive therapies and prolonged hospitalization. Risk factors for the development of ES have not been clearly defined, with conflicting reports as to the role of CD34+ cell dose and pre-ASCT therapy. Defining risk factors could lead to the development of strategies to mitigate the risk of ES. Methods : A cohort of 496 patients who received 596 ASCT for MM between January 2005 and December 2015 was reviewed. ES was defined as a combination of at least 2 symptoms not attributed to other causes including non-infectious fever, diarrhea, skin rash, pulmonary infiltrates or hepatic dysfunction starting from 3 days prior to 10 days post-engraftment. Potential risk factors for the development of ES were analyzed, including age, pre-ASCT therapy, mobilization regimen, pre-ASCT dialysis or radiation therapy, number of CD34+ cells infused, time from diagnosis to transplantation, and disease status at the time of transplantation. Pre-ASCT therapies included lenalidomide (Len), bortezomid (Bor) and Carfilzomib (Car). High risk disease (HRD) was defined as t(14;16), t(14;20), del 17p, t(4;14) or 1q gain by FISH, del 13q, monosomy 13 or hypodiploidy by standard cytogenetics, or high risk signature gene expression profiling. Kaplan Meier and Cox proportional hazard methods were employed. Results: The median age at ASCT was 61 years (range 39-84) and 58% were male. There were 153 incidents of ES by defined criteria, with 123 patients requiring corticosteroids, 6 patients requiring the addition of tacrolimus, and one patient death attributed to ES. Pre-ASCT radiation therapy, time from diagnosis to transplantation and disease status at the time of transplantation were not significantly associated with the development of ES. Patients who received Len (p=0.8840), Bor (p=0.2458), Len and Bor combination (0.6907), or Car (p=0.6818) did not have increased risk of ES. Cyclophosphamide (Cy) for mobilization resulted in higher collection of CD34+ cells, but was not significantly associated with the risk of ES (p=0.6095). The median CD34+ cell dose infused for patients with ES was 5.22 x 10e6/kg versus 5.91 x 10e6/kg for patients without ES. Higher doses of CD34+ cells infused were protective against ES (P=0.0030). Patients with HRD had a significantly higher risk for developing ES, vs patients with standard risk disease (P=0.0041). Patients age 60 and older at the time of ASCT were more likely to develop ES (p=0.0249), and the incidence of ES increased with age up to age 75 . OS by univariate analysis was worse for patients who experienced ES (p=0.0.49). In multivariate analysis, stratified by number of transplants, patients with ES had lower overall survival than patients without ES (p=0.0179) when accounting for HRD, progression and response at ASCT. Conclusions: Pre-ASCT chemotherapy with Bor, Car and/or Len has no effect on the incidence of ES. Stem cell mobilization regimen did not impact the incidence of ES, but higher CD34+ cell doses are protective against ES. Patients without ES have improved overall survival. Older patients are at greater risk for ES, and the risk increases along the age continuum up to age 75. Infusing higher doses of CD34+ cells could be a strategy to mitigate the risk of ES in older patients. Download : Download high-res image (78KB) Download : Download full-size image Figure . Disclosures McKiernan: Novartis: Speakers Bureau. Siegel: Merck: Consultancy; Celgene, Takeda, Amgen Inc, Novartis and BMS: Consultancy, Speakers Bureau. Vesole: Takeda: Speakers Bureau; Celgene: Speakers Bureau. Skarbnik: Novartis: Speakers Bureau; Seattle Genetics: Speakers Bureau; Gilead: Speakers Bureau; Genentech: Speakers Bureau; Abbvie: Other: Ad board, Speakers Bureau. Biran: Celgene, Amgen: Consultancy, Speakers Bureau; Takeda: Speakers Bureau. Richter: Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Speakers Bureau; Janssen: Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Pecora: COTA: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Caladrius Biosciences: Equity Ownership, Membership on an entity's Board of Directors or advisory committees. Goy: Genentech: Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics / JJ Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Acerta: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau." @default.
• W2937138488 created "2019-04-25" @default.
• W2937138488 creator A5004466299 @default.
• W2937138488 creator A5008683298 @default.
• W2937138488 creator A5010673295 @default.
• W2937138488 creator A5023752321 @default.
• W2937138488 creator A5030703994 @default.
• W2937138488 creator A5033124739 @default.
• W2937138488 creator A5033513950 @default.
• W2937138488 creator A5046207755 @default.
• W2937138488 creator A5051483089 @default.
• W2937138488 creator A5056943025 @default.
• W2937138488 creator A5061423277 @default.
• W2937138488 creator A5061941181 @default.
• W2937138488 creator A5070926286 @default.
• W2937138488 creator A5089882481 @default.
• W2937138488 date "2017-12-07" @default.
• W2937138488 modified "2023-09-30" @default.
• W2937138488 title "Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy" @default.
• W2937138488 doi "https://doi.org/10.1182/blood.v130.suppl_1.3284.3284" @default.
• W2937138488 hasPublicationYear "2017" @default.
• W2937138488 type Work @default.
• W2937138488 sameAs 2937138488 @default.
• W2937138488 citedByCount "0" @default.
• W2937138488 crossrefType "journal-article" @default.
• W2937138488 hasAuthorship W2937138488A5004466299 @default.
• W2937138488 hasAuthorship W2937138488A5008683298 @default.
• W2937138488 hasAuthorship W2937138488A5010673295 @default.
• W2937138488 hasAuthorship W2937138488A5023752321 @default.
• W2937138488 hasAuthorship W2937138488A5030703994 @default.
• W2937138488 hasAuthorship W2937138488A5033124739 @default.
• W2937138488 hasAuthorship W2937138488A5033513950 @default.
• W2937138488 hasAuthorship W2937138488A5046207755 @default.
• W2937138488 hasAuthorship W2937138488A5051483089 @default.
• W2937138488 hasAuthorship W2937138488A5056943025 @default.
• W2937138488 hasAuthorship W2937138488A5061423277 @default.
• W2937138488 hasAuthorship W2937138488A5061941181 @default.
• W2937138488 hasAuthorship W2937138488A5070926286 @default.
• W2937138488 hasAuthorship W2937138488A5089882481 @default.
• W2937138488 hasConcept C126322002 @default.
• W2937138488 hasConcept C141071460 @default.
• W2937138488 hasConcept C143998085 @default.
• W2937138488 hasConcept C2776063141 @default.
• W2937138488 hasConcept C2776364478 @default.
• W2937138488 hasConcept C2777408962 @default.
• W2937138488 hasConcept C2779050716 @default.
• W2937138488 hasConcept C2911091166 @default.
• W2937138488 hasConcept C71924100 @default.
• W2937138488 hasConceptScore W2937138488C126322002 @default.
• W2937138488 hasConceptScore W2937138488C141071460 @default.
• W2937138488 hasConceptScore W2937138488C143998085 @default.
• W2937138488 hasConceptScore W2937138488C2776063141 @default.
• W2937138488 hasConceptScore W2937138488C2776364478 @default.
• W2937138488 hasConceptScore W2937138488C2777408962 @default.
• W2937138488 hasConceptScore W2937138488C2779050716 @default.
• W2937138488 hasConceptScore W2937138488C2911091166 @default.
• W2937138488 hasConceptScore W2937138488C71924100 @default.
• W2937138488 hasLocation W29371384881 @default.
• W2937138488 hasOpenAccess W2937138488 @default.
• W2937138488 hasPrimaryLocation W29371384881 @default.
• W2937138488 hasRelatedWork W2474245303 @default.
• W2937138488 hasRelatedWork W2561284235 @default.
• W2937138488 hasRelatedWork W2573952590 @default.
• W2937138488 hasRelatedWork W2726309155 @default.
• W2937138488 hasRelatedWork W2782162829 @default.
• W2937138488 hasRelatedWork W2782702373 @default.
• W2937138488 hasRelatedWork W2906924216 @default.
• W2937138488 hasRelatedWork W2908638985 @default.
• W2937138488 hasRelatedWork W2910367513 @default.
• W2937138488 hasRelatedWork W2913969031 @default.
• W2937138488 hasRelatedWork W2924016392 @default.
• W2937138488 hasRelatedWork W2977427316 @default.
• W2937138488 hasRelatedWork W2980599800 @default.
• W2937138488 hasRelatedWork W2983105338 @default.
• W2937138488 hasRelatedWork W2983857459 @default.
• W2937138488 hasRelatedWork W2984837457 @default.
• W2937138488 hasRelatedWork W2986415439 @default.
• W2937138488 hasRelatedWork W2994975063 @default.
• W2937138488 hasRelatedWork W3095982516 @default.
• W2937138488 hasRelatedWork W3097021036 @default.
• W2937138488 hasVolume "130" @default.
• W2937138488 isParatext "false" @default.
• W2937138488 isRetracted "false" @default.
• W2937138488 magId "2937138488" @default.
• W2937138488 workType "article" @default.